We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Nanocarriers Deploy Enzymes for Targeted Delivery of Anticancer Drugs

By LabMedica International staff writers
Posted on 08 Feb 2016
Print article
Image: Biomedical engineering researchers have developed a technique for creating microscopic “depots” for trapping drugs inside cancer tumors. In an animal model, these drug depots were more effective at shrinking tumors than the use of the same drugs without the depots (Photo courtesy of Quanyin Hu, University of North Carolina).
Image: Biomedical engineering researchers have developed a technique for creating microscopic “depots” for trapping drugs inside cancer tumors. In an animal model, these drug depots were more effective at shrinking tumors than the use of the same drugs without the depots (Photo courtesy of Quanyin Hu, University of North Carolina).
A newly devised nanocarrier delivery system transports a combination of anticancer and anti-angiogenesis drugs to the site of a tumor where the acidic environment releases them to damage the cancer cells and deprive them of nutrients by blocking creation of new blood vessels.

In the January 19, 2016, online edition of the journal Nanoletters investigators at the University of North Carolina (Chapel Hill, USA) described a “transformable” core–shell based nanocarrier (designated CS-NG), which could enzymatically assemble into microscopic extracellular depots at the site of a tumor.

The nanoparticles (approximately 100 nanometers in diameter) consisted of a liposomal core and a cross-linked gel shell containing human serum albumin (HSA). A cocktail comprising the anti-cancer drug TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) and the anti-angiogenesis drug cilengitide was trapped in the aqueous core of the particles. A series of smaller nanoparticles (only 10 nm in diameter) made of a hyaluronic acid gel and containing the enzyme transglutaminase (TG) were attached to the surface of the larger particles.

The rationale for the design of such a complicated construct was that tumors produce large quantities of the enzyme hyaluronidase, which degrades hyaluronic acid. Therefore, when the nanocarriers reach the neighborhood of the tumor, the enzyme would dissolve the small hyaluronic acid gel nanocapsules and release the TG enzymes inside. These would trigger cross-linking of the HSA proteins on the surface of the nanocarriers and create a cross-linked drug depot within the tumor microenvironment. The size of the cross-linked depots would help to prevent them from being absorbed by individual cancer cells or from being dislodged by the bloodstream. Finally, the acidic tumor microenvironment would act to break down the nanoparticles and release the trapped drugs to act on the nearby cancer cells.

Experiments that incorporated the nanocarriers revealed enhanced cytotoxicity on MDA-MB-231 cancer cells growing in culture and improved antitumor efficacy in mice, which was attributed to the inhibition of cellular internalization and prolonged retention time in vivo.

"This is a proof-of-concept study and additional work needs to be done to develop the technique," said senior author Dr. Zhen Gu, assistant professor of biomedical engineering at the University of North Carolina. "But it is promising, and we think this strategy could also be used for cancer immunotherapy. We would need to do more work in an animal model before pursuing clinical trials."

Related Links:

University of North Carolina


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.